Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.55 |
| ▸ | ACACB | O00763 | 1/20 | 0.53 |
| ▸ | ACACA | Q13085 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 8/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524941 | 0.98 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL14269711 | 0.98 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| Gemcabene SCHEMBL528316 | 0.98 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5531453 | 0.98 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL6258161 | 0.98 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| Gemcabene SCHEMBL4184554 | 0.98 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5521484 | 0.96 | ACLY (0.57) | ACLYACACBACACAPPARATTR | |
| SCHEMBL6267270 | 0.96 | ACLY (0.52) | ACLYACACBACACAPPARATTR | |
| SCHEMBL13210381 | 0.94 | ACLY (0.50) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5528996 | 0.93 | ACLY (0.52) | ACLYACACBACACAPPARATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NEUROBO PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | claimed |
| EP-3612176-B1 | COMBINATION COMPRISING THE PPAR AGONIST ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR SELECTED FROM CP-640186, GEMCABENE, GS-0976 TO TREAT INFLAMMATORY, METABOLIC, FIBROTIC OR CHOLESTATIC DISEASES | GENFIT (FR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20250188473-A1 | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | claimed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | claimed |
| US-20240410902-A1 | USE OF SOLUBLE TREM2 AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) | REGION SYDDANMARK (DK) | 2024-12-12 | — | — | US | claimed |
| US-12123001-B2 | Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2024-10-22 | — | — | US | claimed |
| CN-118717997-A | Pharmaceutical composition containing acetyl-CoA carboxylase inhibitor and application thereof | 深圳奥萨制药有限公司 | 2024-10-01 | — | — | CN | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| EP-1045691-A1 | STATIN-CARBOXYALKYLETHER COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-10-25 | — | — | EP | claimed |
| EP-0820428-B1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER LAMBERT CO (US) | 2000-05-10 | — | — | EP | claimed |
| WO-2000018395-A1 | METHOD FOR PREVENTING OR DELAYING CATHETER-BASED REVASCULARIZATION | WARNER-LAMBERT COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-1999030704-A1 | STATIN-CARBOXYALKYLETHER COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
| US-5783600-A | FOR ELEVATING HDL CHOLESTEROL; ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-07-21 | — | — | US | claimed |
| US-5756544-A | ADMINISTERING TO LOWER LEVELS OF LOW DENSITY LIPOPROTEINS AND TO RAISE THE LEVELS OF HIGH DENSITY LIPOPROTEINS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | claimed |
| US-5750569-A | LOWERING PLASMA LIPIDS | WARNER-LAMBERT COMPANY (US) | 1998-05-12 | — | — | US | claimed |
| EP-0820428-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1998-01-28 | — | — | EP | claimed |
| US-5648387-A | Carboxyalkylethers, formulations, and treatment of vascular diseases | WARNER-LAMBERT COMPANY (US) | 1997-07-15 | — | — | US | claimed |
| WO-1996030328-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | INHA, TNNI3, SHBG | ACLY 339/4885ACACB 48/4885ACACA 113/4885 |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | COL1A1, COL2A1, FN1 | ACLY 1133/4885ACACB 115/4885ACACA 150/4885 |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NPC1L1, NOTUM, CEL | ACLY 2298/4885ACACB 1237/4885ACACA 1161/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | ACLY 134/4885ACACB 432/4885ACACA 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.